An interventional study of Abbott HIV-1/2 VL Point of care Device in HIV, Viral Load and Point of Care Monitoring, sponsored by MRC/UVRI and LSHTM Uganda Research Unit. Completed at 7 sites in 4 countries. Open to participants aged 6 Months to 24 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by MRC/UVRI and LSHTM Uganda Research Unit · Not applicable, Interventional, and Diagnostic
The purpose of EAPoC-VL project is to examine the feasibility, acceptability, and effectiveness of using point of care viral load (PoC VL) monitoring to improve viral load suppression among children, adolescents and young people (age ≤24 years) living with HIV in Kenya, Rwanda, Tanzania and Uganda.
Main Study Aims:
i) To determine the effectiveness of PoC VL monitoring in improving viral suppression among children, adolescents and young people living with HIV in East Africa.
ii) To evaluate feasibility and acceptability of using PoC VL monitoring among children, adolescents and young people living with HIV in East Africa.
iii) To understand the psychosocial life of children, adolescents and young people living with HIV in East Africa and how they predict adherence and viral load suppression
Objectives of Aim 1:
Primary objective i. To estimate the effect of PoC VL monitoring on viral load suppression among children, adolescents and young people living with HIV in East Africa at 6 and 12 months of follow-up.
Secondary objectives i. To describe the effect of PoC VL monitoring on the proportion of children, adolescents and young people living with HIV that experiences virological rebound after initial suppression within 6 and 12 months of follow-up.
ii. To describe the effect of PoC VL monitoring on time to initiation of intensive adherence counselling following virological failure among children, adolescents and young people living with HIV.
iii. To estimate the effect of PoC VL monitoring on the proportion of children, adolescents and young people living with HIV that experiences change of ART regimen within 6 and 12 months of follow-up.
iv. To determine the effect of PoC VL monitoring on the proportion of children, adolescents and young people living with HIV that is retained in care at 6 and 12 months.
Objectives of Aim 2 i. To assess the acceptability of the implementation and scale-up of PoC VL testing and monitoring from the perspective of children, adolescents, young people and their caregivers.
ii. To assess the critical determinants that may affect the implementation of PoC VL testing and monitoring from the perspective of healthcare workers and policy makers.
iii. To assess potential barriers and facilitators to implementation and scale-up of PoC VL testing and monitoring among children, adolescents and young people living with HIV.
iv. To assess the incremental cost-effectiveness of PoC VL from a modified societal perspective using established models, with data collected alongside the implementation of the intervention combined with data estimated based on existing studies.
Objectives of Aim 3 i. To psychometrically validate 'psychosocial life' questionnaires. ii. To iteratively develop and psychometrically validate a novel user-friendly tablet-based 'Psychosocial Life' game that predicts adherence and viral load.
iii. To develop and test a set of clinical micro-interventions for psychosocial support based on existing best practice.
iv. To measure how 'psychosocial life' mediates the PoC effect on adherence and viral load.
v. To test proof-of-concept of the use of the novel 'psychosocial life' game and associated micro-interventions in a clinical setting.
Design: A cluster randomized controlled trial with 14 intervention clusters and 14 control clusters.
Study Sites: Twenty (28) health facilities spread across 4 countries as follows: Uganda (8), Kenya (4), Tanzania (12), and Rwanda (4).
Population: The study will be conducted among three population sub-groups
Study Intervention: PoC VL monitoring using Cepheid Gene Xpert machine Control: Standard-of-care / centralized HIV VL monitoring
Duration: The whole project will take 48 months including 24 months of data collection. Each participant will be followed up for approximately 12 months.
Sample size The study will enroll 956 children, adolescents and young people (6months - 24years); with 476 in 14 intervention clusters and 476 in 14 control clusters (34 participants per cluster). The effect of the intervention and 95% CIs will be estimated using cluster-level summary methods and a power of 80%.
Study outcomes of Aim 1 Primary outcomes i. The proportion of children, adolescents and young people living with HIV that achieves viral suppression at 6 and 12 months of follow-up.
ii. The time between enrolment into the study and viral suppression.
Secondary outcomes i. The proportion of children, adolescents and young people living with HIV that experiences virological rebound after initial suppression within 6 and 12 months of follow-up ii. The time between enrolment into the study and initiation of intensive adherence counselling following virological failure.
iii. The proportion of children, adolescents and young people living with HIV that experiences change of ART regimen within 6 and 12 months of follow-up iv. The proportion of children, adolescents and young people living with HIV that is retained in care at 6 and 12 months.
Study outcomes of Aim 2 i. Assessed acceptability of the implementation and scale-up of PoC VL testing and monitoring from the perspective of children, adolescents and young people, and their caregivers.
ii. Identified critical determinants that may affect the implementation of PoC VL testing and monitoring from the perspective of healthcare workers and policy makers.
iii. Identified potential barriers and facilitators to implementation and scale-up of PoC VL testing and monitoring among children, adolescents and young people living with HIV.
iv. An assessment of the incremental cost-effectiveness of PoC VL from a modified societal perspective
Study outcomes of Aim 3 i. Quantified and psychometrically validated measurement of the psychosocial life of children, adolescents and young people living with HIV in East Africa ii. A novel psychometrically validated user-friendly tablet-based 'Psychosocial Life' game that predicts viral load based on psychosocial life.
iii. A list of proposed clinical micro-interventions for psychosocial support based on existing best practice.
iv. A model explaining how psychosocial life indicators mediate the PoC effect on adherence and viral load suppression.
v. A proof-of-concept of the use of the novel 'psychosocial life' game and associated micro-interventions in clinical settings.
Statistical Analysis Aim 1
To investigate the effect of the intervention on viral suppression our analysis will be carried out at the cluster level as follows:
Mixed method Analysis Aim 2 Acceptability and feasibility will be investigated using a combined qualitative and quantitative approach, consisting of thematic content analyses of observations, in-depth interviews and focus group discussions, triangulated and generalized with descriptive statistics of survey data. As part of the feasibility study, the impact of a range of values in sensitivity analyses using each of the respective sites' 2020 per capita GDP as a benchmark cost-effectiveness threshold will be evaluated to be able to estimate the incremental cost-effectiveness of the PoC HIV VL compared to the standard of care. Quality adjusted life years (QALYS) will be calculated based on weights derived from the Global Burden of Disease.
Analysis for Aims 3 Step 1: Determining which psychosocial indicators will be used in the structure equation model on baseline data Pearson correlation analyses will be conducted to examine the strength of associations between all psychosocial life indicator variables and medication adherence. For that, a correlation table will be obtained for looking for multicollinearity. If any two explanatory variables have a Pearson's coefficient of 0.80 or greater one of the variables will be excluded from further analysis as they may measure the same underlying factor.
To determine statistically which psychosocial life indicators have the most predictive power and ascertain the extent to which selected indicators can predict adherence or viral load, a stepwise hierarchical multiple regression will be carried out. Potential predictors will be automatically added into the regression model in steps based on statistical algorithms. Only indicators that significantly improve the overall model fit (R square change) will be retained for the final model of children's psychosocial life.
Step 2: Building a structural equation model and testing how psychosocial life mediates the effect of PoC on adherence and viral load.
Following the RCT design, the goal of this analysis is to measure how psychosocial life indicators mediate the PoC effect on adherence and viral load. An initial hypothetical psychosocial life model will be developed based on variables proved to have the most predictive power obtained from phase one and a synthesis of the empirical literature. The outcome variable will be the change in adherence and viral load separately (difference between baseline and endline data). From the main study (WP1) we assume that PoC improves the medical adherence of children with HIV. We also hypothesize that PoC will improve psychosocial life indicators and that better psychosocial life improves medical adherence and viral load.
Three different types of mediational model will be verified to test the potential mediating role of psychosocial life on the relationship between PoC and medication adherence: (a) a single mediator model, (b) multiple parallel mediator model, and (c) SEM model considering psychosocial life as a latent variable indicated by selected indicators.
MRC/UVRI and LSHTM Uganda Research Unit is the lead sponsor of 14 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Use of point of care viral load monitoring (initially Abbott PoC devices, then changed to Cepheid Gene Xpert)
Diagnostic Test: Abbott HIV-1/2 VL Point of care Device
Use of the standard of care viral load monitoring (centralized viral load monitoring)
Point of care viral load monitoring
The proportion of children, adolescents and young people living with HIV that achieves viral suppression at 6 and 12 months of follow-up.
The proportion of children, adolescents and young people living with HIV that achieves viral suppression at 6 and 12 months of follow-up
Time frame: 36 months
The time between enrolment into the study and viral suppression.
The time between enrolment into the study and viral suppression.
Time frame: 36 months
The proportion of children, adolescents and young people living with HIV that experiences virological rebound after initial suppression within 6 and 12 months of follow-up
The proportion of children, adolescents and young people living with HIV that experiences virological rebound after initial suppression within 6 and 12 months of follow-up
Time frame: 36 months
The time between enrolment into the study and initiation of intensive adherence counselling following virological failure.
The time between enrolment into the study and initiation of intensive adherence counselling following virological failure.
Time frame: 36 months
The proportion of children, adolescents and young people living with HIV that experiences change of ART regimen within 6 and 12 months of follow-up
The proportion of children, adolescents and young people living with HIV that experiences change of ART regimen within 6 and 12 months of follow-up
Time frame: 36 months
The proportion of children, adolescents and young people living with HIV that is retained in care at 6 and 12 months.
The proportion of children, adolescents and young people living with HIV that is retained in care at 6 and 12 months.
Time frame: 36 months
The proportion of children, adolescents and young people and their care givers who accept implementation of PoC VL testing and monitoring
The proportion of children, adolescents and young people and their care givers who accept implementation of PoC VL testing and monitoring.
Time frame: 36 months
The number of factors which may affect the implementation of PoC VL testing and monitoring from the perspective of healthcare workers and policy makers.
The number of factors which may affect the implementation of PoC VL testing and monitoring from the perspective of healthcare workers and policy makers.
Time frame: 24 months
The number of potential barriers and facilitators to implementation and scale-up of PoC VL testing and monitoring identified by children, adolescents and young people living with HIV.
The number of potential barriers and facilitators to implementation and scale-up of PoC VL testing and monitoring identified by children, adolescents and young people living with HIV.
Time frame: 36 months
The incremental cost-effectiveness of PoC VL from a modified societal perspective
The incremental cost-effectiveness of PoC VL from a modified societal perspective
Time frame: 36 months
A psychometrically validated measurement of the psychosocial life of children, adolescents and young people living with HIV in East Africa
Validated psychosocial life questionnaire The psychosocial life questionnaire consists of eight scales measuring different psychosocial indicators (1.motivational readiness scale, 2.Social support scale, 3.Self-efficacy scale, 4.Stigma scale, 5.Patient health questionnaire-9, 6.General anxiety disorder-7, 7. Alcohol use and 8.Quality of life) and only individual scales will be validated. Validation of three scales will be prioritized (1. Stigma scale, 2. Patient health questionnaire-9 and 3. General anxiety disorder-7) measuring three psychosocial indicators (stigma, depression and anxiety) which are the most important predictors of poor medication adherence in East Africa). Each scale, it will be possible to compute the minimum and maximum scores and the higher the score the worse the psychosocial issue. The minimum - maximum score 18-54 , 9-36 and 7-28 for the Stigma scale, Patient health questionnaire-9 and General anxiety disorder-7, respectively.
Time frame: From 12-36 months
A novel psychometrically validated user-friendly tablet-based 'Psychosocial Life' game that predicts viral load based on psychosocial life.
The psychosocial life game will be developed from eight scales of psychosocial life questionnaire; meaning that the psychosocial life game will consist of eight components / sessions, each measuring a specific psychosocial indicator (motivational readiness, social support, self-efficacy, stigma, depression, anxiety, alcohol use or quality of life) predictive of poor medication adherence and viral load suppression. The psychosocial life game will be deployed to HIV clinics and will serve to diagnose a need for psychosocial support among users (adolescents and young people). The game will also be validated against the observed psychosocial needs of the users (i.e. adolescents and youth).
Time frame: From 36-48 months
A list of proposed clinical micro-interventions for psychosocial support based on existing best practice.
The List of micro-interventions for psychosocial support services will be identified from analysis results of qualitative data collected from the four countries on 'best practices on psychosocial support services provided to children, adolescents and young people living with HIV in East Africa.' The analysis report of qualitative data collected on feasibility and acceptability will be reviewed to identify micro-interventions.
Time frame: From 36-48 months
A model explaining how psychosocial life indicators mediate the PoC effect on adherence and viral load suppression.
Explanatory model of the effect of psychosocial life indicators on the PoC effect on adherence and viral load suppression. In this study, psychosocial life indicators (motivational readiness, social support, stigma, depression, anxiety, alcohol use, self-efficacy, quality of life) are mediating indicators between PoC (dependent / explanatory variable) and medication adherence and viral load suppression (outcome variables). Before conducting analysis to construct the model, there will be a need to first assess if there is PoC effect. Due to small sample size, there will be a need to first check if there is an effect of PoC on viral load suppression.
Time frame: From 36-48 months
A proof-of-concept of the use of the novel 'psychosocial life' game and associated micro-interventions in clinical settings.
Proof-of-concept of the use of the novel 'psychosocial life' game. The proof-of-concept will be produced in form of report a mixed methods study that will be conducted to assess feasibility and acceptability of the use of psychosocial life game considering the perspective of end users
Time frame: From 36-48 months
Plan to share: No — Individual Participant Data will be de-identified so as to make it anonymous. This will then be reported either for individuals (e.g. quotations from qualitative interviews) or for study participants as a group.
Ran from Aug 2022 to primary completion in Apr 2025, 32 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
MRC/UVRI and LSHTM Uganda Research Unit